观察咪唑斯汀联合地氯雷他定治疗慢性荨麻疹疗效及对患者睡眠质量的影响

To Observe the Effect of Midazolastine Combined with Desloratadine on Chronic Urticaria and Its Effect on Sleep Quality

目的:观察咪唑斯汀联合地氯雷他定治疗慢性荨麻疹疗效及对患者睡眠质量的影响。方法:选取2018年1月至2019年12月广东省佛山市南海区第八人民医院收治的慢性荨麻疹患者110例作为研究对象,按照随机数字表法分为观察组和对照组,每组55例。对照组给予咪唑斯汀治疗,观察组在对照组基础上加用咪唑斯汀联合地氯雷他定治疗,采用匹兹堡睡眠质量指数(PSQI)量表比较2组患者治疗前后睡眠质量改善情况,同时观察患者免疫功能、氧化应激反应、超氧化物歧化酶的变化情况,并记录不良反应发生情况。结果:治疗前,PSQI评分比较,差异无统计学意义(P>0.05),治疗后,观察组PSQI评分显著低于对照组,2组比较差异有统计学意义(P<0.05);治疗前,2组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平比较差异不明显,2组比较差异无统计学意义(P>0.05),治疗后,观察组较组CD4^(+)、CD4^(+)/CD8^(+)水平显著高于对照组,CD8^(+)水平显著低于对照组,2组比较差异有统计学意义(P<0.05);治疗前,2组丙二醛(MAD)、超氧化物歧化酶(SOD)水平比较,差异无统计学意义(P>0.05),治疗后,观察组MAD水平显著低于对照组,SOD水平显著高于对照组,2组比较差异有统计学意义(P<0.05);治疗后,观察组不良反应发生率显著低于对照组,2组比较差异有统计学意义(P<0.05);观察组治疗总有效率显著高于对照组,2组比较差异有统计学意义(P<0.05)。结论:针对慢性荨麻疹患者采用咪唑斯汀联合地氯雷他定治疗有助于提高临床疗效,改善患者睡眠质量,提高机体氧化应激反应,增强免疫功能,安全性较高。

Objective:To observe the effect of mizolastine combined with desloratadine on chronic urticaria and its effect on sleep quality.Methods:A total of 110 patients with chronic urticaria admitted to the Eighth People′s Hospital of Nanhai District from January 2018 to December 2019 were selected as the research objects,and were divided into observation group and control group according to the random number table method,with 55 patients in each group.The control group was treated with midazolastine,the observation group was treated with midazolastine combined with desloratadine,and Pittsburgh Sleep Quality Index(PSQI)was used.The improvement of sleep quality between 2 groups before and after treatment was compared,and the changes of immune function,oxidative stress response and superoxide dismutase(SOD)were observed,and the occurrence of adverse reactions were recorded.Results:Before treatment,there was no significant difference in PSQI score(P>0.05),but after treatment,PSQI score in observation group was significantly lower than the control group,and the difference between two groups was statistically significant(P<0.05).Before treatment,there was no significant difference in CD4^(^(+)),CD8^(^(+))and CD4^(^(+))/CD8^(^(+))levels between two groups,and there was no statistical difference between two groups(P>0.05).After treatment,CD4^(^(+))and CD4^(^(+))/CD8^(^(+))levels in the observation group were significantly higher than those in the control group,and CD8^(^(+))levels were significantly lower than those in the control group.There was statistically significant difference between the two groups(P<0.05).Before treatment,there was no significant difference in MAD and SOD levels between 2 groups(P>0.05).After treatment,MAD level in the observation group was significantly lower than the control group,and SOD level was significantly higher than control group,with statistical significance(P<0.05).After treatment,the incidence of adverse reactions in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).The total effective rate of observation group was significantly higher than that of control group,and the difference between two groups was statistically significant(P<0.05).Conclusion:For patients with chronic urticaria,the combination of midazolastine and desloratadine can improve the clinical efficacy,improve the sleep quality of patients,improve the oxidative stress response of the body,enhance the immune function,and with high safety.